#Immunosuppressive Drugs Market Share

[mitalipingale]

https://carbonfacesocial.org/blogs/89762/Organ-Transplant-Immunosuppressant-Drugs-Market-Size-Analysis-and-Forecast-2031

The Organ Transplant Immunosuppressant Drugs Market in 2023 is US$ 5.17 billion, and is expected to reach US$ 6.71 billion by 2031 at a CAGR of 3.30%.

[roshankumar7904800]

Focal Segmental Glomerulosclerosis Market

Focal Segmental Glomerulosclerosis (FSGS) Market Size, Share, Trends: Travere Therapeutics, Inc. Leads

Shift Towards Personalized Medicine Approaches in FSGS Treatment

Market Overview:

The Focal Segmental Glomerulosclerosis (FSGS) Market is projected to grow at a CAGR of 6.8% from 2024 to 2031. The market value is expected to increase from USD XX billion in 2024 to USD YY billion by 2031. North America currently dominates the market, accounting for the largest share of global revenue. Key metrics include increasing prevalence of FSGS, advancements in diagnostic technologies, and rising investments in research and development for novel therapies. The market is experiencing steady growth driven by the rising incidence of FSGS, particularly in developed countries, coupled with the growing awareness about rare kidney disorders. Technological advancements in renal pathology and the emergence of targeted therapies are further propelling market expansion, offering new hope for patients with this challenging condition.

DOWNLOAD FREE SAMPLE

Market Trends:

A significant trend in the Focal Segmental Glomerulosclerosis market is the increasing focus on personalized medicine approaches. This shift is driven by the heterogeneous nature of FSGS and the variable response to standard treatments among patients. Researchers and pharmaceutical companies are increasingly exploring genetic and molecular markers that can predict treatment responses and guide therapeutic decisions. For instance, recent studies have identified specific genetic mutations associated with steroid-resistant FSGS, leading to the development of targeted therapies. The adoption of precision medicine in FSGS management is expected to improve treatment outcomes and reduce the risk of unnecessary side effects from ineffective therapies.

Market Segmentation:

Immunosuppressants currently hold the largest market share in the Focal Segmental Glomerulosclerosis treatment segment. This dominance can be attributed to their established efficacy in managing both primary and secondary FSGS, particularly in cases that are resistant to corticosteroid therapy. These drugs, which include calcineurin inhibitors (such as cyclosporine and tacrolimus) and mycophenolate mofetil, have shown significant success in inducing remission and preserving renal function in FSGS patients. Recent clinical evidence supports their use: a meta-analysis published in the Clinical Journal of The American Society of Nephrology found that calcineurin inhibitors were associated with a higher rate of complete or partial remission compared to other therapies in adults with steroid-resistant FSGS.

Market Key Players:

The Focal Segmental Glomerulosclerosis market is highly competitive, with major players focusing on research and development of novel therapies and strategic collaborations. Key companies such as Travere Therapeutics, Inc., Novartis AG, Pfizer Inc., GlaxoSmithKline plc, Apellis Pharmaceuticals, Inc., AstraZeneca plc, Boehringer Ingelheim International GmbH, ChemoCentryx, Inc. (acquired by Amgen), Complexa Inc., and Retrophin, Inc. dominate the market.

Contact Us:

Name: Hari Krishna

Email us: hari.krishna@aurorawaveintellects.com

Website: https://aurorawaveintellects.com/

[kristinahertzz]

Microscopic Polyangiitis Treatment Market

Microscopic Polyangiitis Treatment Market Size, Share, Trends: GlaxoSmithKline plc Leads

Biologics Emerge as Promising Treatment Options Offering Targeted Therapy and Improved Outcomes

Market Overview:

The Microscopic Polyangiitis Treatment Market is witnessing significant growth driven by the rising prevalence of the disease and advancements in treatment options. North America stands out as the fastest-growing region, owing to its advanced healthcare infrastructure and high awareness levels among healthcare professionals. The market encompasses various treatment modalities, including immunosuppressants, biologics, and combination therapies, all aimed at managing this rare autoimmune disease effectively.

The increasing incidence of microscopic polyangiitis and the growing awareness among healthcare providers are key drivers propelling the market forward. Improved diagnostic techniques have led to earlier detection, further fueling the demand for effective treatment options. Additionally, government initiatives and research funding for rare diseases contribute to market expansion, highlighting the importance of innovation in therapeutic approaches. 

DOWNLOAD FREE SAMPLE

Market Trends:

Biologics are emerging as promising treatment options for microscopic polyangiitis, offering targeted therapy and improved outcomes. Recent clinical trials show biologics can induce remission in up to 75% of patients within six months, surpassing traditional therapies. This trend is driven by the precision and efficacy of biologics in targeting specific immune system components involved in the disease.

Market Segmentation:

Immunosuppressants dominate the microscopic polyangiitis treatment market, accounting for the largest market share. These drugs play a crucial role in managing the autoimmune aspects of the disease, offering effective solutions for inducing remission and preventing relapse. Cyclophosphamide and rituximab are prominent immunosuppressants, with recent clinical trials demonstrating their superior efficacy. For instance, rituximab-based regimens achieved complete remission in up to 80% of patients within six months, outperforming traditional therapies. The segment's growth is further fueled by the increasing adoption of combination therapies, which enhance treatment efficacy and reduce the risk of relapse.

In addition to their effectiveness, the introduction of biosimilars has increased the accessibility of immunosuppressants, especially in emerging markets. Biosimilars have led to a 30% reduction in treatment costs, making these therapies more affordable for a broader patient population. This trend is expected to continue, solidifying immunosuppressants' position as the cornerstone of microscopic polyangiitis treatment.

Market Key Players:

Prominent players in the microscopic polyangiitis treatment market include GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd, Genentech, Inc., ChemoCentryx, Inc., Novartis AG, and Bristol-Myers Squibb Company. These companies are at the forefront of innovation, continuously investing in research and development to bring advanced therapies to market.

Contact Us:

Name: Hari Krishna

Email us: hari.krishna@aurorawaveintellects.com

Website: https://aurorawaveintellects.com/

[market-insider]

Anterior Uveitis Treatment Market In-Depth Study: Evaluating Market Size, Share, Growth Forecast

The global anterior uveitis treatment market size is expected to reach USD 967.5 million by 2030, registering a CAGR of 12.6% from 2024 to 2030, according to a new report by Grand View Research, Inc. Rising prevalence of the disease is anticipated to aid market growth. This disease is more common when compared to panuveitis, posterior, and intermediate uveitis.

Anterior Uveitis Treatment Market Report Highlights

Corticosteroids dominated the anterior uveitis treatment market in 2023 owing to its beneficial characteristic of minimizing inflammation in the eye. It is the primary treatment modality.

Anti-TNF agents are expected to exhibit lucrative growth rate over the forecast period due to growing opportunity in treatment methods with biologic therapy using Anti-TNF drugs.

Immunosuppressants held a significant market share in 2023 owing to their growing adoption for treatment of chronic anterior uveitis.

Hospital pharmacies dominated the market in 2023 due to the wide treatment options available there.

Online pharmacies are expected to witness significant CAGR over the forecast period due to convenience, ease, and availability of discounted products.

North America held the largest revenue share in 2023 owing to high prevalence as well as healthcare expenditure in this region.

Asia Pacific is anticipated to exhibit lucrative growth during the forecast period due to the rising number of infectious diseases in developing countries of the region and growing disposable income.

For More Details or Sample Copy please visit link @: Anterior Uveitis Treatment Market Report

According to a 2017 article by Retina Today, this condition accounted for around 30% to 90% of the cases of uveitis. It also stated around 1% to 4% of patients experience 25% loss of visual acuity. There are different effective treatments for this disease and can be easily managed; however, it tends to recur. This disease is prevalent among both young and middle-aged group. It is also common among the geriatric population. Ocular ischemia and herpetic uveitis are the two most common causes of this disease among the geriatric population. Most of the cases occur in healthy people, however, some are associated with infectious diseases, gastrointestinal disorders, rheumatologic diseases, and lung & skin diseases. This disease is less sight-threatening as compared to posterior uveitis, however, in some cases might lead to glaucoma, cataract, and cystoid macular edema.

List Of major companies in the Anterior Uveitis Treatment Market

Novartis AG

Santen Pharmaceutical Co., Ltd.

AbbVie Inc.

Kiora Pharmaceuticals, Inc.

Clearside Biomedical

Aldeyra Therapeutics, Inc.

Aciont Inc.

Sirion Therapeutics, Inc.

UCB S.A.

Lux Biosciences, Inc.

For Customized reports or Special Pricing please visit @: Anterior Uveitis Treatment Market Analysis Report

We have segmented the global anterior uveitis treatment market based on type, therapy, distribution channel, and region.

[industrynewsupdates]

Understanding Insulin Market: Trends and Growth Drivers

The global insulin market is expected to reach USD 23.20 billion by 2030, expanding at a CAGR of 1.5% during the forecast period, according to a new report by Grand View Research, Inc. It is an oligopolistic space dominated by companies such as Novo Nordisk A/S, Sanofi, and Eli Lilly and Company. The increasing incidence of diabetes and formulation advancements in insulin delivery are the primary factors driving growth. However, the presence of biosimilars and drugs such as GLP-1 RAs for the treatment of type 2 diabetes can slow down market growth to a certain extent.

Diabetes is one of the fastest-growing chronic diseases in the world. Its prevalence has increased steadily over the past few decades. The prevalence of the disease is growing rapidly in low- and middle-income countries; three in four adults live with diabetes in these countries. According to the International Diabetes Federation (IDF) data from 2021, approximately 643 million individuals will have diabetes by 2030 and 783 million by 2045. In addition, the increase in geriatric and obese populations is another factor driving growth. The overweight population is at risk of developing type 2 diabetes mellitus. According to WHO, in 2020, 1.9 billion adults were found to be overweight, accounting for 39% of the population within that age group.

Gather more insights about the market drivers, restrains and growth of the Insulin Market

Insulin Market Report Highlights

��� The long-acting insulin segment contributed a significant revenue share of 56.53% in 2021. Factors such as patent protection and high demand due to long-term effects are expected to drive the segment

• Type 1 diabetes mellitus is the largest segment by application in 2021 due to the high insulin dependency of these patients

• Insulin analog segment dominated in 2021. It is due to the higher efficacy of insulin and minimal adverse effects, such as hypoglycemic attacks and lower weight gain, as compared to conventional therapy

• The retail pharmacy segment dominated the distribution channel in 2021 due to the presence of retail pharmacy chains and tie-ups of these chains with hospitals

• North America dominated the market in terms of revenue in 2021, mainly due to the dominance of branded products and the increasing prevalence of diabetes in the region

Browse through Grand View Research's Pharmaceuticals Industry Research Reports.

• The global celiac disease treatment market size was valued at USD 582.5 million in 2023 and is projected to grow at a CAGR of 11.8% from 2024 to 2030.

• The global organ transplant immunosuppressant drugs market size was valued at USD 5.51 billion in 2024 and is projected to grow at a CAGR of 4.7% from 2025 to 2030. 

Insulin Market Segmentation

Grand View Research has segmented the global Insulin market based on product type, application, type, distribution channel, and regions:

Insulin Product Type Outlook (Revenue, USD Million, 2018 - 2030)

• Rapid-Acting Insulin

• Long-Acting Insulin

• Combination Insulin

• Biosimilar

• Others

Insulin Type Outlook (Revenue, USD Million, 2018 - 2030)

• Human Insulin

• Insulin Analog

Insulin Application Outlook (Revenue, USD Million, 2018 - 2030)

• Type 1 Diabetes Mellitus

• Type 2 Diabetes Mellitus

Insulin Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals

• Retail Pharmacies

• Others

Insulin Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

o U.S.

o Canada

• Europe

o Germany

o UK

o France

o Italy

o Spain

• Asia Pacific

o Japan

o China

o India

o Australia

o South Korea

• Latin America

o Brazil

o Mexico

o Argentina

• Middle East and Africa (MEA)

o South Africa

o Saudi Arabia

o UAE

Order a free sample PDF of the Insulin Market Intelligence Study, published by Grand View Research.

[marketingreportz]

Stem Cell Banking Market - Forecast(2024 - 2030)

Stem Cell Banking Market Overview

Request sample Report :

The ongoing research in stem cells has the capability to understand how diseases occur, and various conditions develop. Cord tissue banking has been adopted as the potential method to store life-saving stem cells for any future injuries or chronic diseases. The advent of regenerative medicines and the use of stem cells to check quality and safety before releasing a new batch of drugs have been key factors driving the stem cell banking industry forward in the projected period of 2021–2026.

Report Coverage

The report: “Stem Cell Banking Market Forecast (2021–2026)” by Industry ARC covers an in-depth analysis of the following segments of the Stem Cell Banking Market.

By Source- Placental Stem Cell, Adipose-Tissue Derived Stem Cells, Bone Marrow-Derived Stem Cells, Human Embryo Derived Stem Cell, Dental Pulp Derived Stem Cells and Others.

By Service Type- Sample Preservation and Storage, Sample Analysis, Sample Processing, and Sample Collection and Transportation.

By Application- Personalized Banking, Research Applications, and Clinical Applications.

By Geography- North America (U.S., Canada, Mexico), Europe (Germany, United Kingdom (U.K.), France, Italy, Spain, Russia, and Rest of Europe), Asia Pacific (China, Japan India, South Korea, Australia, and New Zealand, and Rest of Asia Pacific), South America (Brazil, Argentina, and Rest of South America), and Rest of the World (the Middle East, and Africa).

Inquiry Before Buying :

Key Takeaways

Geographically, North America’s stem cell banking held a dominant market share in the year 2020. It is owing to the advent of various genetic disorders and the rise in the use of regenerative medicines. Additionally, the region is seeing an inflated flow of funds for development pertaining to the pharmaceutical and biotechnology sector which has readily aided the market growth. However, Asia-Pacific is set to grow at a lucrative pace in the projected period. It is owing to the development of new-age start-ups which thereby allows for the opening of various stem cell banking systems using advanced healthcare technology such as IoT.

The growing awareness pertaining to the use of therapeutic potential stem cells has been a key driver for the market. However, high operational costs and maintenance fees are some of the reasons the market is facing friction and poses a challenge.

A detailed analysis of strengths, weaknesses, opportunities, and threats will be provided in the stem cell banking market report.

Stem Cell Banking Market- Geography (%) for 2020.

For more details on this report — Request for Sample

Stem Cell Banking Market Segmentation Analysis- By Source

The stem cell banking market based on the source can be further segmented into Placental Stem Cell, Adipose-Tissue Derived Stem Cells, Bone Marrow-Derived Stem Cells, Human Embryo Derived Stem Cell, Dental Pulp Derived Stem Cells and Others. The Bone marrow-derived stem cells held a dominant market share in the year 2020. It is owing to its standard use in the treatment of cancer cases such as leukemia, myeloma, and various others. Bone marrow-derived stem cells are also considered privileged immune cells, as they do not portray immunogenic properties and hence are used in patients who then do not need immunosuppression. Moreover, there are close to 4300 bone marrow and cord blood transplants recorded in 2018, while nearly 23 million potential donors are available.

However, Human Embryo Stem cells are estimated to be the fastest-growing, with a CAGR of 8.4% over the forecast period of 2021–2026. The embryonic stem cell is obtained potentially after 3–5 days, and it has about 150 cells. Moreover, the following pluripotent stem cells have the capability to divide into more stem cells or become any form of cell. Their versatility has allowed the researchers to use them in various applications pertaining to regenerative medicines or to especially regenerate a diseased tissue or organ.

Schedule A Call :

Stem Cell Banking Market Segmentation Analysis- By Application

The stem cell banking based on the application can be further segmented into Personalized Banking, Research Applications, and Clinical Applications. Personalized banking held a dominant market share in the year 2020. It is owing to the various benefits now being co-offered with availing services. The service provider has curated various flexible payment plans to later the financial burden on the end-user. For example, Cord Blood Registry has payment plans starting from as low as $49/month. Additionally, they have started promoting themselves under “highest recovery rate- up to 99%”, which readily appeals to the public’s confidence, as recovery is often a worry in cases of stem cell banking.

Moreover, personalized banking is estimated to be the fastest-growing, with a CAGR of 8.6% over the forecast period of 2021–2026. The advent of insurance policies in the service provider has proved out to be a game-changer. Sample banking companies reimburse in cased of failed graft, however owing to competition, the bankers have really notched up their payback rates. For example, Ameri-Cord now pays around $110,000 as insurance, with no monthly storage fees and cancellation fees. The following methodology would drive the segment forward.

Stem Cell Banking Market Segmentation Analysis- By Geography

The Stem Cell Banking Market based on Geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. North America’s stem cell banking held a dominant market share of 42% as compared to the other regions in 2020. It is owing to the rising cases of cancers and other neurodegenerative diseases in the region. For example, in the U.S., approximately 1.9 million were diagnosed with Cancer; moreover, post-cancer stem cell therapy is often recommended as it helps in restoring the damaged cells. The cells are damaged owing to chemotherapy and other forms. Along with that, the incidence of Parkinson’s disease is high in the country, and the ongoing research has helped the market of stem cell banking across various applications.

However, Asia-Pacific is set to offer lucrative market opportunities to marketers in the projected period of 2021–2026. It is owing to a steady rise in the new players opting for facilities such as stem cell banking. Additionally, governmental agencies have supported the start-up culture in the health care domain, which allows for the development of new drugs, which again supports the growth of stem cells. These factors would help in the growth of the following region.

Stem Cell Banking Market Drivers

The use of stem cell therapy or regenerative medicines has readily aided market growth.

Stem cell therapy has often been conferred as the next chapter after organ transplantation. As they are termed regenerative medicines, they promote repair response in the diseased cells. The following cells are used instead of donor’s organs, as they have the potential to provide a healthy line of cells that are free of any disease or infection. Researchers grow these cells in their labs and are thereby manipulated to form other forms of distinctive cells. For example, if a patient is suffering from heart disease, then they can be used and injected into the heart muscle. The healthy line of cells could repair the defective heart cells and contribute to a better life expectancy. Stem cell therapy can readily suffice the demand and supply gap between organ transplants. For example, the demand for a kidney transplant in the USA was close to 100,000; however, only close to 20,000 people received the transplant. The demand for the remaining can be catered by stem cell therapy, and hence, grow the stem cell banking market.

Buy Now :

The lateral increase in auto-immune diseases and the elongated use of stem cells to check for effectiveness in new drugs have readily aided the growth of the market.

Stem cell therapy has shown results in treating those afflicted with spinal cord injuries, suffering from type 1 diabetes, Parkinson’s disease, and various other rare diseases. As per Parkinson’s Organization, approximately more than 60,000 cases of the disease are added in the USA. Moreover, there are currently more than one million-plus active cases of the disease in the demography. Researchers are readily studying the use of stem cell therapy in the treatment of Parkinson’s disease. Stem cells can be directly injected into the brains of people, and a doctor must make a small incision and inject stem cells where the neurotransmitter dopamine is found. The process can take hold and thereby start producing dopamine which is negligible in the person suffering from Parkinson’s disease. Lastly, the cost of such treatment would be on the lower side and hence allow more people to take advantage of it.

Stem Cell Banking Market Challenges

The operational cost pertaining to storage and other facilities has acted as a market challenge.

The stem cells or the embryonic stem cells are often derived from the umbilical cord. A lot of competition has already been in place for the market. However, the cost of storing stem cells in a bank remains a primary concern. The pricing for storing cord tissue or stem cells, on average, can cost $4000/ a year. Additionally, facilities always face the risk of losing the sample’s integrity owing to various physical constraints. The reagents, consumables, and other instruments are charged on premium, which in turn increases the per-person cost. The process for acquiring licenses has been another challenge as regulatory bodies follow a stringent approach. Hence, the number of providers and new entrants are not many, and hence poses a market challenge.

Stem Cell Banking Market Competitive Landscape

Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the stem cell banking. The top 10- stem cell banking market companies include:

Cord Blood Registry

Americord

CryoCell

StemCyte

Viacord

Lifebank USA

Miracle Cord

Maze Cord Blood

CryoHoldco

CordLife Group Limited

Stem Cell Banking Market Developments

In September 2021, The California Institute for Regenerative Medicines awarded $31 million to Stanford Researchers. The amount is granted to study stem cells and conduct the first-in-human trials of stem cells to treat stroke, heart failure, and other forms of neurodegenerative diseases. The $31 million is divided into various other purposes, for example, $12 million would allow for the study, whether after therapy with stem cell one can regain mobility. The second study, in which $ 12 million would be used to study CAR-T cell therapy. Another, $7 million is to be used to study stem cells’ ability to help in aiding heart failures.

In January 2020, Life-Cell launched community stem cell banking services in India. The enterprise would be known as Baby Cord Share. The purpose of the launch was to allow for the ready availability of finding a matching donor in a challenging environment. The price to avail of the services is kept at INR 17000, while an annual maintenance fee of INR 4,000 would be charged from the customer.

Relevant Titles

Tissue Banking Market — Forecast (2021–2026)

Report Code- HCR 0014

Extremity Tissue Expanders Market- Forecast (2021–2026)

Report Code- HCR 1448

For more Lifesciences and Healthcare related reports, please click here

[marketsndata]

Global Rheumatoid Arthritis Therapeutics Market Size, Share, Growth and Forecast 2031

Global rheumatoid arthritis therapeutics market is projected to witness a CAGR of 5.58% during the forecast period 2024-2031, growing from USD 30.05 billion in 2023 to USD 46.39 billion in 2031. The market’s growth is bolstered by the rising cases of rheumatoid arthritis, increasing research activities to improve the understanding of the disease, and growing approvals from different regulatory bodies across the globe. The expansion of the geriatric population is also augmenting the cases of rheumatoid arthritis. As per the World Health Organization (WHO) estimates, one in six people across the globe will be sixty or older by 2030, and by 2050, approximately 2.1 billion people will be sixty or older. Rheumatoid arthritis affects the synovial joints and causes inflammation that can result in loss of function and joint damage over a period of time.

Additionally, increasing the provision of approvals for drugs for rheumatoid arthritis by different regulatory bodies ensures that patients worldwide have access to the necessary medication. In October 2024, Alfasigma S.p.A. received the green light for the commercialization of Jyseleca, a JAK1 drug used for ulcerative colitis and rheumatoid arthritis, following the approval received from the European Medicines Agency. The transfer of marketing authorization for the drug in the European Union was completed after the company purchased the medication for USD 186 million.

Moreover, the growing acceptance of biosimilars, the economically efficient alternatives to biologic drugs with similar therapeutic effects, bolsters the global rheumatoid arthritis therapeutics market size. Major pharmaceutical companies actively invest in approving and developing new biosimilars and biologics, positively influencing the market’s growth. Additionally, different research organizations and market players across the globe are actively investing in developing novel therapies that offer fewer side effects than traditional therapies. They also engage in collaborations by pooling their resources and expertise; the organizations can reduce the time required for drug development and easily address the unmet medical requirements of the patients. 

Increasing Prevalence of Rheumatoid Arthritis Boosts Market Demand

The rising cases of rheumatoid arthritis can be attributed to the expansion of the aging population and changing lifestyles. The increasing disease burden is augmenting the global demand for rheumatoid arthritis therapeutics. As per the estimates of Johns Hopkins University & Medicine, rheumatoid arthritis has a prevalence of 1% to 2%, along with a worldwide distribution. The prevalence of the disease is approaching 5% among women who are older than 55. Autoimmune disease is characterized by the inflammation of joint tissue and exhibits deformation of small joints, pain, and swelling in approximately half of the patient population. Additionally, the development and availability of sensitive testing methods allow patients to receive an early diagnosis, further propelling the requirement for rheumatoid arthritis therapeutics. After the detection of the condition, early treatments such as immunosuppressive drug therapy and nonsteroidal anti-inflammatory drugs are initiated. Additionally, women are more susceptible to the disease as the female immune cells produce more inflammatory cytokines, proteins that control immune cell activity and control inflammation.

Investments in Research Activities Support Market Expansion

The increasing emphasis on research activities for addressing the complexities of the disease and the discovery of novel treatments is aiding researchers in developing advanced therapeutic solutions for rheumatoid arthritis and providing lucrative growth opportunities to the market. One of the promising research areas in the disease is the exploration of biological agents that are responsible for targeting unique immune pathways that play a role in inflammation. In July 2024, SetPoint Medical Corporation announced positive topline results for the RESET-RA clinical study. The clinical study evaluates the use of the SetPoint System as a potential neuroimmune modulation treatment for individuals with moderate to severe rheumatoid arthritis who are intolerant to targeted synthetic or biologic disease-modifying anti-rheumatic drugs or incomplete responders. A significant portion of the patient population suffering from rheumatoid arthritis is either intolerant to the approved treatment options available or adequately responding to them. Moreover, the approved immunotherapies also have severe immunosuppressive risks that can result in low treatment adherence, safety concerns, and poor patient satisfaction. Such clinical research studies are expected to augment the development of therapeutic systems that improve treatment outcomes by increasing patient adherence, among others.

Biopharmaceuticals Account for Significant Market Share

The segment’s expansion can be attributed to the increasing research studies showcasing the different benefits associated with various biopharmaceuticals. According to an article published in the JAMA Network of the American Medical Association in June 2024, treatment sequences initiated by biosimilar disease-modifying antirheumatic drugs (DMARDs) were shown to be cost-effective in comparison with treatment sequences initiated with leflunomide in patients suffering from rheumatoid arthritis as per a study conducted by a team of researchers from the University of Hong Kong. Such studies highlight the financial feasibility and benefits associated with biosimilar drugs, resulting in their increasing demand.

Additionally, the comparative effectiveness analysis published in the Rheumatology Journal of the Oxford University Press in September 2023 showed that patients who were switched from etanercept originator to biosimilar had similar drug persistence and disease activity as those patients who remained on the originator, thus indicating nonmedical switching does not have a detrimental effect on treatment outcomes. The study was conducted with the help of data from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA), which tracks patients with rheumatoid arthritis who start targeted or biologic DMARDs.

North America Holds Major Market Share

The expansion of the market in North America can be attributed to the growing prevalence of rheumatoid arthritis in the region, the strong presence of leading market players and research organizations, the rapid growth of the aging population, and the growing emphasis on personalized healthcare. As per the estimates of Johns Hopkins University & Medicine, the average annual incidence of rheumatoid arthritis in the United States is 70 per 100,000 annually. Additionally, the United States Food and Drug Administration (USFDA) is providing approvals for generic drugs for rheumatoid arthritis to increase patient access. In August 2023, Zydus Lifesciences Limited received final approval from the USFDA for manufacturing and marketing their generic suppositories indicated for moderate to severe rheumatoid arthritis. Approval has been given to Zydus for marketing and manufacturing their Indomethacin suppositories at 50 mg strength. Indomethacin suppositories are anti-inflammatory and non-steroidal drugs indicated for rheumatoid arthritis, including moderate to severe ankylosing spondylitis, acute flares of chronic disease, moderate to severe osteoarthritis, acute gouty arthritis, and acute painful shoulder. Additionally, the rising investments from the leading market players in the region towards novel product development and launches and enhancement of their research and development capabilities are further propelling the availability of novel therapeutic solutions in North America, providing lucrative growth opportunities to the rheumatoid arthritis therapeutics market.

Download Free Sample Report

Future Market Scenario (2024-2031F)

As per the global rheumatoid arthritis therapeutics market analysis, the market is expected to witness significant growth in the coming years due to the rising cases of rheumatoid arthritis, increasing awareness about the different treatment options, increasing innovation in therapies, and rising shift towards personalized medicines. According to the estimates of an article published in The Lancet of Elsevier Ltd. in October 2023, the number of cases of rheumatoid arthritis is forecasted to increase by 80.2% between 2020 and 2050, and 31.7 million individuals will be living with the disease by 2050 across the globe. Additionally, different healthcare and government organizations are also working on increasing awareness about the impact of treatment adherence and early diagnosis on patients with rheumatoid arthritis.

Moreover, various healthcare organizations are also investing in treatment programs for healthcare professionals to ensure they are updated on the advancements in the treatments for rheumatoid arthritis. Such efforts are expected to bolster the demand for the global rheumatoid arthritis therapeutics market in the coming years. Regulatory bodies, healthcare professionals, and pharmaceutical companies are expected to play a crucial role in allowing for a patient-centric and effective approach to treating rheumatoid arthritis and ensuring the availability of the required therapeutic solutions.

Report Scope

“Rheumatoid Arthritis Therapeutics Market Assessment, Opportunities and Forecast, 2017-2031F”, is a comprehensive report by Markets and Data, providing in-depth analysis and qualitative and quantitative assessment of the current state of global rheumatoid arthritis therapeutics market, industry dynamics, and challenges. The report includes market size, segmental shares, growth trends, opportunities, and forecast between 2024 and 2031. Additionally, the report profiles the leading players in the industry, mentioning their respective market share, business models, competitive intelligence, etc.

Click here for full report- https://www.marketsandata.com/industry-reports/rheumatoid-arthritis-therapeutics-market

Latest reports-

Contact

Mr. Vivek Gupta 5741 Cleveland street, Suite 120, VA beach, VA, USA 23462 Tel: +1 (757) 343–3258 Email: info@marketsandata.com Website: https://www.marketsandata.com

[amrutatbrc1]

Lupus Therapeutics Market 2024-2033 : Demand, Trend, Segmentation, Forecast, Overview And Top Companies

The lupus therapeutics global market report 2024 from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.

Lupus Therapeutics Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.

Market Size -

The lupus therapeutics market size has grown strongly in recent years. It will grow from $2.53 billion in 2023 to $2.74 billion in 2024 at a compound annual growth rate (CAGR) of 8.6%. The growth in the historic period can be attributed to the increased prevalence of lupus, increased investment in healthcare infrastructure, high disposable income, high demand for effective therapies, and rising geriatric population.

The lupus therapeutics market size is expected to see strong growth in the next few years. It will grow to $3.83 billion in 2028 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to rising drug approvals and launches, emerging markets, improvements in disease awareness and diagnosis, rising awareness initiatives, and immunosuppressive products. Major trends in the forecast period include chimeric antigen receptor T-cell (CAR-T) therapy, small molecule therapeutics for lupus, CAR-NK therapy for lupus, combined inhibition of human plasmacytoid dendritic cell activity during systemic lupus, erythematosus (SLE), urine proteomics.

Order your report now for swift delivery @

The Business Research Company's reports encompass a wide range of information, including:

1. Market Size (Historic and Forecast): Analysis of the market's historical performance and projections for future growth.

2. Drivers: Examination of the key factors propelling market growth.

3. Trends: Identification of emerging trends and patterns shaping the market landscape.

4. Key Segments: Breakdown of the market into its primary segments and their respective performance.

5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.

6. Macro Economic Factors: Assessment of broader economic elements impacting the market.

Market Drivers -

The increasing research and development activities are expected to propel the growth of the lupus therapeutics market going forward. Research and development activities refer to systematic investigation and experimentation aimed at advancing knowledge, technology, or product development in various fields. The increasing research and development activities is often driven by the need for innovation, advancements in technology, addressing emerging challenges, improving healthcare outcomes, and fostering economic growth through scientific discoveries and technological breakthroughs. Research and development activities help advance lupus therapeutics by discovering new treatments, improving existing therapies, and understanding the underlying mechanisms of the disease. For instance, in March 2023, according to a report published by the Congressional Research Service, a US-based federal legislative branch agency, the national institutes of health received $49.183 billion in 2023 for research and development activities, marking an increase from $42.941 billion allocated in 2021. Therefore, the increasing research and development activities are driving the growth of the lupus therapeutics market.

Market Trends -

Major companies operating in the lupus therapeutics market are focused on developing advanced blood tests with predictive artificial intelligence to enhance diagnostic accuracy and treatment efficacy. Blood tests with predictive artificial intelligence refer to diagnostic tools that use AI algorithms to analyze biomarkers in blood samples, predicting disease outcomes or treatment responses with greater accuracy. For instance, in March 2024, AMPEL BioSolutions LLC, a US-based precision medicine company, launched the LuGENE blood test, which predicts lupus flares and drug targets from gene expression utilizing predictive artificial intelligence (AI). The test is designed to revolutionize the management of lupus, an autoimmune disease, by providing personalized treatment options for patients. It identifies real-time abnormalities in gene expression that lead to inflammation and immune system dysfunction, which are targetable by medication.

The lupus therapeutics market covered in this report is segmented –

1) By Disease Type: Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus, Drug-Induced Lupus Erythematosus, Neonatal Lupus

2) By Treatment Type: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Biologics, Antimalarial Drugs, Corticosteroids, Other Treatment Types

3) By Route Of Administration: Oral, Subcutaneous, Intravenous, Other Routes Of Administration

4) By End User: Hospitals And Clinics, Diagnostic Laboratories, Other End Users

Get an inside scoop of the lupus therapeutics market, Request now for Sample Report @

Regional Insights -

North America was the largest region in the lupus therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lupus therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Key Companies -

Major companies operating in the lupus therapeutics market are <b>Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Sanofi SA, AstraZeneca PLC, Novartis AG, Roche Holdings Inc., GlaxoSmithKline plc, Eli Lilly and Company, Viatris Inc., Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma, Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Lupin Ltd, Zydus Lifesciences Limited, Glenmark Pharmaceuticals Limited</b>

Table of Contents

1. Executive Summary

2. Lupus Therapeutics Market Report Structure

3. Lupus Therapeutics Market Trends And Strategies

4. Lupus Therapeutics Market – Macro Economic Scenario

5. Lupus Therapeutics Market Size And Growth

…..

27. Lupus Therapeutics Market Competitor Landscape And Company Profiles

28. Key Mergers And Acquisitions

29. Future Outlook and Potential Analysis

30. Appendix

Contact Us:

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Email: info@tbrc.info

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Twitter: https://twitter.com/tbrc_info

Facebook: https://www.facebook.com/TheBusinessResearchCompany

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Blog: https://blog.tbrc.info/

Healthcare Blog: https://healthcareresearchreports.com/

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

[heathcareforallworld]

Ocular Inflammation Therapeutics Market Growth and Trends: Forecast to 2032

The Ocular Inflammation Therapeutics Market is expected to witness significant growth over the forecast period leading to 2032. Ocular inflammation refers to swelling, redness, and discomfort caused by various conditions affecting the eye, such as uveitis, keratitis, conjunctivitis, and scleritis. These conditions can arise from infections, autoimmune disorders, or trauma, potentially leading to vision loss if not treated promptly. The increasing prevalence of eye-related disorders, advancements in treatment options, and the growing elderly population are key factors propelling the market's expansion.

Ocular Inflammation Therapeutics Market Size was estimated at 14.16 (USD Billion) in 2023. The Ocular Inflammation Therapeutics Market Industry is expected to grow from 14.89(USD Billion) in 2024 to 22.2 (USD Billion) by 2032. The Ocular Inflammation Therapeutics Market CAGR (growth rate) is expected to be around 5.12% during the forecast period (2025 - 2032).

Market Growth Drivers

Rising Prevalence of Ocular Inflammatory Conditions The increasing incidence of eye diseases, particularly among the aging population, is a major factor driving the demand for ocular inflammation therapeutics. Conditions such as uveitis, which affects the uveal tract of the eye, are increasingly diagnosed globally. According to the American Academy of Ophthalmology, uveitis is responsible for 10% to 15% of cases of total blindness in the U.S. alone. Other conditions such as scleritis and keratitis are also contributing to the rising demand for effective treatments.

Increasing Awareness and Early Diagnosis Awareness campaigns promoting eye health and early diagnosis of ocular inflammatory diseases are contributing to market growth. With advancements in diagnostic technologies, such as Optical Coherence Tomography (OCT) and fundus imaging, clinicians are better equipped to identify inflammation in its early stages. This leads to more prompt and effective treatment, enhancing patient outcomes and driving the demand for therapeutic solutions.

Advancements in Therapeutics and Drug Development Innovations in the field of ocular drug delivery and therapy are helping boost the market. The development of biologics, immunosuppressants, and corticosteroid formulations has transformed the treatment landscape for ocular inflammation. For example, corticosteroid implants and injectable therapies offer sustained drug release, providing long-term relief from chronic conditions like uveitis. Additionally, novel biologic therapies are emerging as targeted treatments that offer fewer side effects compared to traditional options, thus increasing adoption.

Market Segmentation

The Ocular Inflammation Therapeutics Market can be segmented based on drug class, indication, distribution channel, and geography.

By Drug Class: The market is segmented into corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), immunosuppressants, and biologics. Corticosteroids currently hold the largest share due to their widespread use in treating inflammation, although biologics are expected to see the highest growth owing to their targeted action and fewer side effects.

By Indication: Key conditions treated include uveitis, keratitis, conjunctivitis, and scleritis. Uveitis accounts for a significant portion of the market due to its frequency and potential severity.

By Distribution Channel: The primary distribution channels are hospital pharmacies, retail pharmacies, and online pharmacies. With the increasing prevalence of e-commerce and telemedicine, online pharmacies are expected to witness notable growth over the forecast period.

Key Market Trends

Biologics Gaining Traction Biologic therapies are gaining ground in the ocular inflammation therapeutics market due to their precision in targeting specific pathways involved in the inflammatory response. Biologics like adalimumab have shown significant efficacy in treating severe uveitis, reducing the need for long-term corticosteroid use and minimizing associated side effects. As more biologic treatments receive regulatory approvals, their use is expected to expand, fueling market growth.

Rising Focus on Sustained Drug Delivery The development of sustained drug delivery systems for ocular therapeutics is a growing trend. Implants and injectables that deliver medications over an extended period are becoming more popular, especially for chronic conditions like posterior uveitis. These systems improve patient compliance, reduce the frequency of dosing, and provide more consistent therapeutic outcomes.

Increasing Use of Immunosuppressants Immunosuppressants, traditionally used in organ transplantation, are now being repurposed for treating ocular inflammatory conditions, particularly in patients unresponsive to corticosteroids. Drugs like cyclosporine and tacrolimus are gaining traction as they offer long-term control of inflammation without the side effects of prolonged steroid use.

Regional Analysis

North America holds the largest share of the ocular inflammation therapeutics market due to its advanced healthcare infrastructure, high prevalence of eye diseases, and growing geriatric population. The U.S. remains a major contributor to market growth, with high healthcare spending and an increasing number of clinical trials focused on novel therapies for ocular inflammation.

Europe follows closely, with countries like Germany, France, and the U.K. leading the way in adopting advanced ocular treatments. Awareness campaigns and government initiatives aimed at preventing vision impairment are driving market demand in this region.

Asia-Pacific is expected to witness the fastest growth during the forecast period, driven by improving healthcare infrastructure, increasing access to treatment, and a large, aging population. The rising incidence of diabetes, a key risk factor for ocular inflammation, further propels the demand for therapeutics in countries like India and China.

Competitive Landscape

Key players in the AbbVie ,Novartis ,Pfizer ,Roche ,Allergan ,Regeneron ,Alcon ,Takeda ,Iluvien ,Bausch & Lomb ,Biogen ,Santen ,Bayer ,Merck & Co ,Johnson & Johnson. These companies are focusing on product development, strategic collaborations, and mergers and acquisitions to strengthen their market presence. Ongoing research into new drug formulations, biologics, and drug delivery systems is expected to create new growth opportunities in the coming years.

Conclusion

The Ocular Inflammation Therapeutics Market is poised for substantial growth through 2032, driven by increasing awareness of eye health, advancements in drug development, and the rising prevalence of ocular inflammatory conditions. Innovations in biologics, sustained drug delivery systems, and early diagnosis technologies will continue to shape the market. As the demand for effective therapies grows, especially in emerging markets, key players in the industry are well-positioned to capitalize on these opportunities, driving future expansion.

[credenceresearchdotblog]

The Immunomodulator Market is projected to grow from USD 88579.7 million in 2024 to an estimated USD 148816 million by 2032, with a compound annual growth rate (CAGR) of 6.7% from 2024 to 2032.The immunomodulator market has emerged as a critical component of global healthcare, driven by advancements in biotechnology, increasing incidence of autoimmune diseases, and the rising prevalence of cancer and infectious diseases. Immunomodulators, which regulate or modify the immune system, include immunosuppressants, immunostimulants, and others that either enhance or suppress immune activity. The growing awareness of immune-related disorders, coupled with the rise in biologics and personalized medicine, positions the immunomodulator market as one of the fastest-growing segments in the pharmaceutical industry.

Browse the full report at https://www.credenceresearch.com/report/immunomodulator-market

Market Overview

The global immunomodulator market has witnessed remarkable growth in recent years, with significant advancements in therapies targeting autoimmune diseases, cancer, and chronic inflammatory conditions. According to market reports, the immunomodulator market is expected to grow at a compound annual growth rate (CAGR) of around 5-7% over the next decade. Several factors are driving this growth, including the increasing prevalence of diseases like rheumatoid arthritis, multiple sclerosis, lupus, and psoriasis, where the immune system malfunctions and attacks the body's tissues.

Moreover, immunomodulators have gained traction in oncology. They are used to boost the body's immune response against cancerous cells, which has made a significant impact on cancer treatment approaches. Additionally, the market is expanding in the area of infectious diseases, especially with the development of vaccines and treatments for diseases like COVID-19, HIV, and hepatitis.

Key Drivers of the Immunomodulator Market

1. Rising Prevalence of Autoimmune Diseases Autoimmune diseases have seen a sharp rise over the past few decades, with millions of people worldwide affected by conditions like type 1 diabetes, rheumatoid arthritis, Crohn’s disease, and systemic lupus erythematosus. The complex nature of these diseases often requires long-term treatment with immunomodulators to manage symptoms and prevent flare-ups, which has driven demand for more effective therapies.

2. Increase in Cancer Cases and Immunotherapy Adoption The integration of immunomodulators in cancer therapy, particularly in the form of checkpoint inhibitors and monoclonal antibodies, has revolutionized cancer treatment. Immunotherapy drugs like pembrolizumab (Keytruda) and nivolumab (Opdivo) have shown great promise in treating cancers like melanoma, non-small cell lung cancer, and renal cell carcinoma. The success of these therapies is driving further research and investment in this sector, increasing the market share of immunomodulators in oncology.

3. Advances in Biotechnology and Biopharmaceuticals The development of biopharmaceuticals has led to the creation of more targeted and effective immunomodulators. Unlike traditional drugs, biologics are derived from living organisms and are designed to mimic or enhance the body's natural immune response. The growing number of biopharmaceutical companies investing in research and development (R&D) of immunomodulators has fostered innovation, leading to novel therapies for hard-to-treat conditions.

4. Increasing Geriatric Population The aging population is another factor contributing to the growth of the immunomodulator market. As people age, their immune systems weaken, making them more susceptible to autoimmune diseases, cancers, and infections. Immunomodulators are increasingly being used to help manage these conditions in elderly populations, which is expected to contribute significantly to market growth.

Challenges and Limitations

Despite the promising growth, the immunomodulator market faces several challenges. One major issue is the high cost of biologic therapies, which can limit access to these treatments, especially in low- and middle-income countries. Additionally, side effects such as increased susceptibility to infections and certain types of cancer can be a concern for long-term users of immunosuppressants.

There is also the challenge of balancing immune suppression with immune enhancement. Suppressing the immune system too much can lead to infections, while overstimulating it may trigger autoimmune diseases. Therefore, finding the right therapeutic window for immunomodulators remains a challenge for healthcare providers and researchers.

Regional Insights

North America holds the largest share of the global immunomodulator market, primarily due to the high prevalence of autoimmune diseases and cancer, as well as the availability of advanced healthcare infrastructure and significant investment in R&D. Europe follows closely, with similar factors driving market growth, including favorable government policies that support biopharmaceutical innovation.

Meanwhile, the Asia-Pacific region is expected to witness the fastest growth, attributed to the rising incidence of chronic diseases, increasing healthcare expenditure, and expanding biopharmaceutical industries in countries like China, Japan, and India. The growing middle class and improved access to healthcare services in these regions are further bolstering market expansion.

Future Outlook

The immunomodulator market is poised for sustained growth as researchers continue to unlock the complexities of the immune system. The ongoing development of new immunotherapies, combined with advancements in personalized medicine and targeted therapies, will likely drive innovation in this sector. Moreover, as healthcare systems around the world continue to prioritize the management of chronic diseases and cancer, the demand for immunomodulators will remain robust.

Key Player Analysis:

Abbott

Amgen Inc.

Biogen

Bristol-Myers Squibb Company

Eli Lilly and Company

Hoffmann-La Roche Ltd

Johnson & Johnson Services, Inc.

Merck & Co., Inc.

Novartis AG

Pfizer Inc

Segmentation:

By Product

Biologics,

Small molecules,

Other emerging therapies.

By Application

Autoimmune diseases,

Cancer,

Infectious diseases,

Others

By Region

North America

The U.S

Canada

Mexico

Europe

Germany

France

The U.K.

Italy

Spain

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

South-east Asia

Rest of Asia Pacific

Latin America

Brazil

Argentina

Rest of Latin America

Middle East & Africa

GCC Countries

South Africa

Rest of Middle East and Africa

Browse the full report at https://www.credenceresearch.com/report/immunomodulator-market

About Us:

Credence Research is committed to employee well-being and productivity. Following the COVID-19 pandemic, we have implemented a permanent work-from-home policy for all employees.

Contact:

Credence Research

Please contact us at +91 6232 49 3207

Email: sales@credenceresearch.com

Website: www.credenceresearch.com

[roshankumar7904800]

Uveitis Treatment Market

Uveitis Treatment Market Size, Share, Trends: AbbVie Inc. Leads

Adoption of Biologics and Targeted Therapies Gains Momentum in Uveitis Treatment

Market Overview:

The uveitis treatment market is estimated to grow at a XX% CAGR between 2024 and 2031. According to estimates, the market will be worth USD XX billion in 2024 and USD YY billion in 2031. North America is likely to dominate the market throughout the forecast period. The expanding prevalence of uveitis, breakthroughs in biologics and immunosuppressants, and improved awareness of ocular inflammatory illnesses are all major contributors.

The uveitis treatment market is gradually growing, thanks to an increase in uveitis cases across all age groups, breakthroughs in diagnostic techniques, and the development of novel therapy approaches. The use of targeted biologics and combination therapy is changing uveitis management, giving more efficacy and fewer side effects than traditional corticosteroid treatments.

DOWNLOAD FREE SAMPLE

Market Trends:

The uveitis treatment market is rapidly shifting towards the use of biologics and tailored therapy. These novel medications offer more tailored immunomodulation than classic broad-spectrum immunosuppressants, which may increase efficacy while reducing systemic side effects. Adalimumab, a TNF-α inhibitor, has demonstrated promising effects for treating non-infectious uveitis. A multicenter study published in the New England Journal of Medicine in 2023 discovered that patients treated with adalimumab were 50% less likely to experience uveitis flares than those given a placebo. Similarly, tocilizumab, an interleukin-6 receptor antagonist, has demonstrated efficacy in patients with refractory uveitis. This trend is driving market innovation, with pharmaceutical companies investing heavily in the development of novel biologics aimed specifically at ocular inflammatory diseases. The shift to personalised medicine in uveitis therapy is also gaining traction, with researchers investigating biomarkers to predict treatment response and guide therapeutic choice. This strategy has the potential to improve treatment outcomes while minimising healthcare expenses associated with ineffective medications.

Market Segmentation:

Corticosteroids have maintained their position as the dominant segment in the uveitis therapy market, owing to their early onset of action, broad anti-inflammatory benefits, and flexibility in administration routes. Because of their ability to quickly reduce inflammation and retain vision, these drugs remain the first line of treatment for many kinds of uveitis. According to a comprehensive review published in the Journal of Ophthalmic Inflammation and Infection in 2023, corticosteroids were used as the first-line treatment in more than 80% of acute uveitis cases in major ophthalmology centres worldwide.

Recent advancements in corticosteroid formulations have increased their market dominance. For example, extended-release intravitreal implants, such as Allergan's Ozurdex (dexamethasone), have revolutionised the treatment of chronic and recurrent uveitis. A multicenter clinical trial published in Ophthalmology in 2024 discovered that persons treated with dexamethasone implants had a 60% reduction in uveitis recurrence rates compared to typical topical corticosteroid therapy over a two-year period.

Market Key Players:

AbbVie Inc.

Novartis AG

Allergan plc (now part of AbbVie)

Bausch Health Companies, Inc.

Eyepoint Pharmaceuticals, Inc.

Alimera Sciences, Inc.

Contact Us:

Name: Hari Krishna

Email us: hari.krishna@aurorawaveintellects.com

Website: https://aurorawaveintellects.com/

[colinwilson11]

Digitalization Will Propel The Bullous Pemphigoid Market Growth Owing To Increased Diagnosis Accuracy

The Bullous Pemphigoid Market involves treating a rare autoimmune disease wherein the immune system attacks the skin and mucous membranes resulting in large fluid-filled blisters and vesicles on the skin and mucosal membrane. Bullous Pemphigoid primarily affects the elderly population above the age of 60 and leads to extensive itching and pain. The main treatment modalities involve immunomodulatory medications such as corticosteroids, anti-inflammatory drugs, and immunosuppressive medications to ease symptoms.

The Bullous Pemphigoid Market is estimated to be valued at US$ 1.4 Bn in 2024 and is expected to exhibit a CAGR of 10% over the forecast period 2024-2031.

Key players operating in the Bullous Pemphigoid market are GlaxoSmithKline, Novartis, Pfizer, AstraZeneca, and Roche. These companies offer a range of treatment options from oral and topical corticosteroids to immunosuppressive therapies. The increasing geriatric population prone to developing bullous pemphigoid coupled with rising awareness regarding the condition is expected to drive the growth of the market. Additionally, advancements in diagnosis facilitated by digital imaging technologies assist in prompt diagnosis and treatment of the condition, thereby improving treatment outcomes.

Key Takeaways

Key players analysis: Key players operating in the Bullous Pemphigoid market are GlaxoSmithKline, Novartis, Pfizer, AstraZeneca, and Roche. GlaxoSmithKline leads the market with drugs including Rituximab and Benlysta.

Growing demand: The growing geriatric population accounted for a major share of the bullous pemphigoid patient pool. According to the WHO, the number of people aged 60 years and older is expected to double by 2050. This significantly drives the demand for bullous pemphigoid treatment.

Technological advancement: Advancements in digital imaging and teledermatology allow accurate diagnosis of bullous pemphigoid through visualization of skin lesions via smartphones and teleconsultation. This enables early intervention and superior management of the condition.

Market Trends

Combination therapies: There is a growing trend of using drug combinations as opposed to monotherapies to effectively manage bullous pemphigoid. Popular combinations involve corticosteroids with immunosuppressants.

Targeted biologic agents: Novel targeted biologic agents aimed at specific antibodies and immune pathways involved in bullous pemphigoid show promise. Drugs like Rituximab, Inebilizumab, and Eculizumab are being evaluated for efficacy and safety.

Market Opportunities

Emerging economies: Countries in Asia Pacific and Latin America present lucrative opportunities for bullous pemphigoid treatment providers owing to growing medical needs of their aging population and economic expansion.

Online consultations: Telehealth and e-pharmacy platforms allow people to remotely access bullous pemphigoid specialists and medication, thereby overcoming distance barriers. This increases access to care.

Impact Of COVID-19 On Bullous Pemphigoid Market Growth

The COVID-19 pandemic has significantly impacted the growth of the bullous pemphigoid market. During the initial phases of the pandemic between 2020-21, the market witnessed a decline in growth rate owing to lockdowns imposed across various countries. This led to postponement of non-essential dermatological procedures and treatments. Patients also avoided visiting healthcare facilities fearing exposure to the virus. As a result, diagnosis and treatment rates for bullous pemphigoid reduced considerably during this period.

However, with lifting of lockdowns and rollout of vaccination drives globally, the market has started recovering post 2021. Increased awareness about the autoimmune disorder and availability of effective treatment options are supporting the growth trajectory. Various initiatives undertaken by key market players to ensure uninterrupted supply of drugs and therapies have also boosted market revenues. For instance, companies streamlined their production and distribution channels to meet the rising demand. Teleconsultations further aided continued care for patients during lockdowns.

Going forward, the bullous pemphigoid market is expected to witness robust expansion supported by ageing population prone to developing the condition. Moreover, rapid advancements in biologics and targeted therapies will expand treatment options. Players are investing heavily in R&D to develop novel pipeline drugs. Favorable regulatory environment and reimbursement policies will augment market access. Widespread vaccination drives and resumption of normal healthcare activities will further accelerate market growth in the coming years.

Europe holds the largest share of bullous pemphigoid market in terms of value owing to sizeable patient pool and high treatment uptake. North America follows Europe in terms of revenue generation led by rising disease prevalence and advanced healthcare infrastructure. Asia Pacific is recognized as the fastest growing regional market and will continue exhibiting strong growth momentum through 2031. This can be attributed to improving access to diagnosis and treatment options due to expanding healthcare expenditure in countries like China and India.

Geographical Regions With Highest Bullous Pemphigoid Market Value

North America accounts for the largest share of the Bullous Pemphigoid Market value-wise. The region is estimated to hold over 35% revenue share of the overall market in 2024 led by strong presence of leading pharmaceutical companies in US and Canada. Increased focus on research into novel treatment options along with supportive reimbursement policies are driving the growth of the North America bullous pemphigoid market.

Europe holds the second largest value share globally on account of rising burden of the autoimmune disorder due to aging population. Countries like Germany, UK, France, Italy are major revenue generators for Europe bullous pemphigoid market. High healthcare expenditure and availability of affordable treatments make Europe an attractive regional market.

Geographical Region Witnessing Fastest Growth In Bullous Pemphigoid Market

Asia Pacific region has emerged as the fastest growing geographical market for bullous pemphigoid globally. The Asia Pacific bullous pemphigoid market is projected to expand at a CAGR of over 12% during 2024-2031. Factors such as growing geriatric demographic, increasing medical awareness regarding bullous pemphigoid diagnosis and management, rising healthcare spending, and improving access to advanced drugs are fueling the market growth. Countries like India, China, Japan, and South Korea are expected to drive substantial revenues for bullous pemphigoid treatment manufacturers within Asia Pacific market.

Get more insights on this topic:  https://www.ukwebwire.com/bullous-pemphigoid-market-growth-to-be-fueled-by-advancements-in-targeted-therapies/

Author Bio:

Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163 )

What Are The Key Data Covered In This Bullous Pemphigoid Market Report?

:- Market CAGR throughout the predicted period

:- Comprehensive information on the aspects that will drive the Bullous Pemphigoid Market's growth between 2024 and 2031.

:- Accurate calculation of the size of the Bullous Pemphigoid Market and its contribution to the market, with emphasis on the parent market

:- Realistic forecasts of future trends and changes in consumer behaviour

:- Bullous Pemphigoid Market Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa

:- A complete examination of the market's competitive landscape, as well as extensive information on vendors

:- Detailed examination of the factors that will impede the expansion of Bullous Pemphigoid Market vendors

FAQ’s

Q.1 What are the main factors influencing the Bullous Pemphigoid Market?

Q.2 Which companies are the major sources in this industry?

Q.3 What are the market’s opportunities, risks, and general structure?

Q.4 Which of the top Bullous Pemphigoid Market companies compare in terms of sales, revenue, and prices?

Q.5 Which businesses serve as the Bullous Pemphigoid Market’s distributors, traders, and dealers?

Q.6 How are market types and applications and deals, revenue, and value explored?

Q.7 What does a business area’s assessment of agreements, income, and value implicate?

*Note: 1. Source: Coherent Market Insights, Public sources, Desk research 2. We have leveraged AI tools to mine information and compile it

[adityarana1687-blog]

Transplantation Market Size To Reach $30.9 Billion By 2030

The global transplantation market size is expected to reach USD 30.9 billion by the year 2030, expanding at a CAGR of 9.3%, according to a new report by Grand View Research, Inc.  Growing incidence of organ failure has resulted in massive growth in the transplantation market.

Rising demand for transplant products such as tissue products, immunosuppressants, and organ preservation solutions is a major factor anticipated to boost the market’s growth during the forecast period. Thus, many biotechnology and medical device companies have begun to concentrate on the development of advanced transplant products for the management of organ failure.

Technological advancement in organ transplantation methods is another major factor supporting the market growth. The development of novel & improved transplant products such as tissue products and surgical instruments has majorly contributed to the expansion of the sector.

In addition, the introduction of advanced tissue products such as DeNovo NT Graft, Chondrofix Osteochondral Allograft, and DuraMatrix Collagen Dura Substitute Membrane provides higher benefits during treatment.  In addition, computerized support systems with advanced systems and software allow easy & effective maintenance of tissues. Thus, the availability of such advanced techniques supports an increase in the number of organ transplant procedures.

Request a free sample copy or view report summary: Transplantation Market Report

Transplantation Market Report Highlights

Tissue products segment was the largest revenue-generating amongst others due to escalating number of tissue and organ transplant procedures

Tissue products segment is also expected to rise at the highest CAGR owing to advancements in transplantation products

Tissue transplant segment held the largest revenue share in the market, because of the rising number of skin, bones, heart valves, cornea, tendons, nerves, and veins procedures worldwide

The transplant centers segment is projected to expand at the highest CAGR during the forecast period owing to rising popularity of these centers for transplant procedures

The hospitals segment dominated the market in terms of revenue in 2022 owing to a large number of transplant procedures performed in hospitals

North America was the leading regional sector in 2022 and is projected to maintain its dominance during the forecast period owing to well-developed healthcare infrastructure

Existence of a large number of research laboratories, biotechnology, and medical device companies in the North America region is the major factor contributing to its large share

Transplantation Market Segmentation

Grand View Research has segmented the global transplantation market on product, application, end-use, and region:

Transplantation Product Outlook (Revenue, USD Million; 2018 - 2030)

Tissue Products

Immunosuppressive Drugs

Preservation Solution

Transplantation Application Outlook (Revenue, USD Million; 2018 - 2030)

Organ Transplantation

Tissue Transplantation

Transplantation End Use Outlook (Revenue, USD Million; 2018 - 2030)

Hospitals

Transplant Centers

Others

Transplantation Regional Outlook (Revenue, USD Million; 2018 - 2030)

North America

U.S.

Canada

Europe

U.K.

Germany

France

Italy

Spain

Denmark

Sweden

Norway

Asia Pacific

China

Japan

India

Australia

South Korea

Thailand

Latin America

Brazil

Mexico

Argentina

Middle East and Africa

Saudi Arabia

South Africa

UAE

Kuwait

List of Key Players in Transplantation Market

AbbVie, Inc.

Arthrex, Inc.

Zimmer Biomet

Medtronic

Novartis AG

Stryker

21st Century Medicine

BioLifeSolutions, Inc

Teva Pharmaceuticals

Veloxis Pharmaceuticals

[industrynewsupdates]

Transplantation Market Forecast: Growth, Trends, and Opportunities

The global transplantation market was valued at USD 15.0 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 9.3% from 2023 to 2030. This growth is primarily driven by the increasing demand for innovative tissue and organ transplantation products, which are essential for the treatment of organ failure. Organ failure can result from a variety of factors, including severe trauma, blood loss, poisoning, drug abuse, leukemia, sepsis, and other acute illnesses. Among the most critical and sought-after organ transplants are those of the kidney, heart, liver, and lungs, with the demand for these transplants being particularly high worldwide.

The rising incidence of organ failure is largely attributable to unhealthy lifestyles, which are increasingly common across the globe. Factors such as poor dietary habits, alcohol consumption, lack of physical exercise, and substance abuse are major contributors to the decline in organ function and the need for transplants. As these issues continue to affect populations globally, the demand for organ and tissue transplants, as well as transplantation-related products, is expected to escalate over the coming years.

Factors Driving Market Growth

Several key factors are contributing to the expansion of the transplantation market:

1. Increased Demand for Transplants: As the incidence of organ failure rises, particularly in developed nations with high rates of chronic diseases, there is an increasing demand for organ transplants. The most commonly transplanted organs—kidneys, hearts, livers, and lungs—are in critical demand, driven by the growing prevalence of end-stage renal disease (ESRD), heart disease, and chronic liver diseases.

2. Advances in Transplantation Technologies: Technological innovations in transplant medicine, including improvements in organ preservation, immunosuppressive treatments, and surgical techniques, have significantly increased the success rates of transplant surgeries. This, in turn, has contributed to the growing popularity of organ transplantation as a treatment option.

3. Ageing Populations: In many parts of the world, particularly in developed countries, the population is ageing, leading to an increased incidence of age-related diseases such as cardiovascular diseases and kidney dysfunction, which necessitate organ transplants.

Gather more insights about the market drivers, restrains and growth of the Transplantation Market

Regional Insights

North America 

In 2022, North America led the global transplantation market with a dominant market share of 39.0%, and this trend is expected to continue throughout the forecast period. The region benefits from highly developed healthcare infrastructure, a strong regulatory framework, and the presence of major biotechnology and medical devices companies. Leading companies such as Arthrex, Inc., Zimmer Biomet, Medtronic, Novartis AG, and Stryker have significant operations in the region, contributing to the continued growth of the transplantation market. These companies play an important role in the development and commercialization of innovative transplantation solutions, further bolstering the market’s expansion.

The demand for organ transplants in North America has outpaced the availability of donated organs, particularly for critical organs like the kidney, liver, and heart. Over the last decade, the gap between the supply and demand for these organs has widened significantly. However, the region has witnessed substantial efforts from governments, non-governmental organizations (NGOs), and healthcare institutions to bridge this gap. These efforts include campaigns aimed at raising awareness about organ donation, improving donor registration processes, and implementing new policies that streamline the donation system.

For example, in 2020, the Human Resource & Services Administration (HRSA) launched the Hospital Organ Donor Campaign, which aimed to encourage hospitals and healthcare providers to increase the number of organ donations. This initiative resulted in a notable rise in organ donations in 2020 compared to the previous year. These continued efforts are expected to improve the availability of transplant organs and further stimulate the market growth in the region.

Asia Pacific Market Outlook

The Asia Pacific region is projected to experience the highest growth rate in the transplantation market during the forecast period, driven by several key factors:

1. Research on Stem Cells and In-Vitro Organ Development: The region has seen significant advancements in stem cell research aimed at developing in-vitro tissues and organs for transplantation. Countries like India, China, and others are investing heavily in biotechnological innovations, which is expected to drive demand for new transplant solutions.

2. Improving Healthcare Infrastructure: Countries in Asia, including India, Thailand, the Philippines, and Indonesia, are rapidly developing their healthcare systems, particularly in urban areas, where the demand for organ transplants is increasing. As these nations improve their medical infrastructure, the availability of transplant-related products and services is expected to expand, further stimulating market growth.

3. Rising Incidences of Chronic Diseases: The growing prevalence of chronic diseases, including heart disease, diabetes, and renal failure in the Asia Pacific region, is contributing to an increased need for organ transplants. The rising burden of these diseases, coupled with aging populations, is expected to fuel the demand for transplantation services.

Browse through Grand View Research's Medical Devices Industry Research Reports.

• The global probe reprocessing market size was valued at USD 844.87 million in 2024 and is anticipated to grow at a CAGR of 10.55 % from 2025 to 2030.

• The global surgical helmet market size was estimated at USD 79.50 million in 2024 and is projected to grow at a CAGR of 4.77% from 2025 to 2030. 

Key Companies and Market Share Insights

The transplantation market is highly fragmented, with numerous large, small, and medium-sized vendors operating across various regions. Some of the leading companies in the market include:

• Zimmer Biomet

• Medtronic

• Stryker Corporation

These industry leaders are actively engaged in product innovation, mergers and acquisitions, and regional expansion strategies to capture a larger market share. For example, strategic mergers and acquisitions enable companies to expand their product offerings and geographical reach, allowing them to better serve the growing demand for transplantation products globally.

An example of such innovation is the world's first robotic lung transplant, performed in April 2023 by a team of surgeons in Spain. The procedure used a robotic system known as Da Vinci, representing a significant leap forward in the field of organ transplantation. This novel robotic lung transplant procedure underscores the ongoing advancements in surgical technologies and highlights the increasing role of robotics and automation in transplantation surgeries.

Additionally, the market is witnessing a surge in the development of advanced technologies, such as 3D bioprinting, which holds the potential to revolutionize organ transplantation by enabling the regeneration of tissues and organs. In September 2020, CollPlant Biotechnologies, an Israeli biotech company, and United Therapeutics announced a collaboration to utilize 3D bioprinting for the development of human kidneys for transplantation. This partnership marks a significant milestone in the efforts to bioengineer functional organs, which could address the global organ shortage and improve transplant outcomes in the future.

Some of the prominent players in the global transplantation market include:

• Abbvie, Inc

• Arthrex, Inc.

• Zimmer Biomet

• Medtronic

• Novartis AG

• Strykers

• 21st Century Medicine

• BiolifeSolutions, Inc

• Teva Pharmaceuticals

• Veloxis Pharmaceutical

Order a free sample PDF of the Transplantation Market Intelligence Study, published by Grand View Research.

[businessindustry]

Bronchiolitis Obliterans Syndrome Treatment Market Growth, Analysis Report by 2032

The Reports and Insights, a leading market research company, has recently releases report titled “Bronchiolitis Obliterans Syndrome Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2032.” The study provides a detailed analysis of the industry, including the global Bronchiolitis Obliterans Syndrome Treatment Market Analysis share, size, trends, and growth forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.

Report Highlights:

How big is the Bronchiolitis Obliterans Syndrome Treatment Market?

The global bronchiolitis obliterans syndrome treatment market was valued at US$ 72.6 Million in 2023 and is expected to register a CAGR of 4.1% over the forecast period and reach US$ 104.2 Million in 2032.

What are Bronchiolitis Obliterans Syndrome Treatment?                                                                                                                                                                            

Bronchiolitis obliterans syndrome (BOS) is a severe, irreversible lung disease characterized by inflammation and scarring of the bronchioles, which leads to airway obstruction. Treatment focuses on symptom management, slowing disease progression, and enhancing quality of life. Key therapies include immunosuppressive medications like corticosteroids and calcineurin inhibitors to reduce inflammation and immune activity. Other treatments may involve macrolide antibiotics for their anti-inflammatory effects, pulmonary rehabilitation, and, in extreme cases, lung transplantation. Effective management also requires monitoring and addressing complications, such as infections, to improve patient outcomes.

Request for a sample copy with detail analysis: https://www.reportsandinsights.com/sample-request/2386

What are the growth prospects and trends in the Bronchiolitis Obliterans Syndrome Treatment industry?

The bronchiolitis obliterans syndrome (BOS) treatment market growth is driven by various factors and trends. The bronchiolitis obliterans syndrome (BOS) treatment market is expanding due to increased awareness and diagnosis, advancements in medical research, and the development of innovative therapies. Leading companies are focusing on new treatments, including enhanced immunosuppressive drugs, anti-inflammatory agents, and potential gene therapies. The market is driven by the demand for effective management strategies and the necessity of lung transplantation in severe cases. Collaborations between pharmaceutical companies and research institutions, along with government initiatives, are also fostering market growth. However, high treatment costs and limited access to advanced therapies in certain regions pose ongoing challenges. Hence, all these factors contribute to bronchiolitis obliterans syndrome (BOS) treatment market growth.

What is included in market segmentation?

The report has segmented the market into the following categories:

By Drug Type

Immunosuppressive Drugs

Biologics

Antibiotics

Others

By Stage Type

Phase I

Phase II

Advanced Stage

By Treatment Type

Pharmaceutical

Corticosteroids

Immunosuppressants

Other Medications

Non-Pharmaceutical

Lung Transplant

Lung Rehabilitation

By End-user

Hospitals

Specialty Clinics

Others

North America

United States

Canada

Europe

Germany

United Kingdom

France

Italy

Spain

Russia

Poland

Benelux

Nordic

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

ASEAN

Australia & New Zealand

Rest of Asia Pacific

Latin America

Brazil

Mexico

Argentina

Middle East & Africa

Saudi Arabia

South Africa

United Arab Emirates

Israel

Rest of MEA

Who are the key players operating in the industry?

The report covers the major market players including:

Breath Therapeutics

Genentech

Incyte Corporation

Zambon Company S.P.A.

Mallinckrodt plc

Mereo BioPharma

Altavant Sciences

Koutif Therapeutics

Renovion Inc.

Orphai Therapeutics

View Full Report: https://www.reportsandinsights.com/report/Bronchiolitis Obliterans Syndrome Treatment-market

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us:

Reports and Insights consistently mееt international benchmarks in the market research industry and maintain a kееn focus on providing only the highest quality of reports and analysis outlooks across markets, industries, domains, sectors, and verticals. We have bееn catering to varying market nееds and do not compromise on quality and research efforts in our objective to deliver only the very best to our clients globally.

Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.

Contact Us:

Reports and Insights Business Research Pvt. Ltd. 1820 Avenue M, Brooklyn, NY, 11230, United States Contact No: +1-(347)-748-1518 Email: sales@reportsandinsights.com Website: https://www.reportsandinsights.com/ Follow us on LinkedIn: https://www.linkedin.com/company/report-and-insights/ Follow us on twitter: https://twitter.com/ReportsandInsi1

[trendingreportz]

Multiple Sclerosis Drugs Market - Forecast(2024 - 2030)

Multiple Sclerosis Drugs Market Overview

The Multiple Sclerosis Drugs Market size is estimated to reach $31.3 billion by 2028, growing at a CAGR of 3.7% during the forecast period 2023-2028. Treatment of multiple sclerosis may involve immunosuppressants, immunomodulators and monoclonal antibodies. Interferons are disease-modifying drugs that assist in decreasing relapses in people enduring multiple sclerosis. Intramuscular injections are utilized when additional kinds of delivery techniques like oral, intravenous and subcutaneous are not suggested. As per a novel clinical trial in August 2022, an experimental antibody therapy for multiple sclerosis can reduce symptom flare-ups by half, as compared to standard treatment. Interferon beta-1a has been certified by the U.S. Food and Drug Administration (FDA) to treat relapsing forms of multiple sclerosis and it has been assessed in clinical trials for the treatment of COVID-19. According to the National Multiple Sclerosis Society, more than 2.8 million people are living with Multiple Sclerosis worldwide. The burgeoning focus of firms on pipeline products for multiple sclerosis is set to drive the Multiple Sclerosis Drugs Market. The recommended continuous medicines for multiple sclerosis-like interferons to decrease the requirement for hospitalization due to COVID-19 are set to propel the growth of the Multiple Sclerosis Drugs Industry during the forecast period 2023-2028. This represents the Multiple Sclerosis Drugs Industry Outlook.

Multiple Sclerosis Drugs Market Report Coverage

The “Multiple Sclerosis Drugs Market Report - Forecast (2023-2028)” by IndustryARC, covers an in-depth analysis of the following segments in the Multiple Sclerosis Drugs Market.

By Drug Class: Immunomodulators, Immunosuppressants, Interferons and Others.

By Route Of Administration:Oral, Injection (Intramuscular, Subcutaneous and Intravenous).

By Geography: North America (the US, Canada and Mexico), Europe (Germany, France, the UK, Italy, Spain, Russia and the Rest of Europe), Asia-Pacific (China, Japan, South Korea, India, Australia & New Zealand and the Rest of Asia-Pacific), South America (Brazil, Argentina, Chile, Colombia and the Rest of South America) and the Rest of the World (the Middle East and Africa).

Request Sample

Key Takeaways

Geographically, North America (Multiple Sclerosis Drugs market share) accounted for the highest revenue share in 2022. It is poised to dominate the market over the period 2023-2028 owing to the increasing predominance of multiple sclerosis involving immunomodulators in the North American region.

The growth of the Multiple Sclerosis Drugs Market is being driven by considerable financing of large pharmaceutical firms in the drug development procedure and surging interferon treatment of Multiple Sclerosis. However, the soaring cost of medications is one of the major factors hampering the growth of the Multiple Sclerosis Drugs Market.

The Multiple Sclerosis Drugs Market Detailed Analysis of the Strengths, Weaknesses and Opportunities of the prominent players operating in the market would be provided in the Multiple Sclerosis Drugs Market report.

Multiple Sclerosis Drugs Market Segment Analysis - by Drug Class

The Multiple Sclerosis Drugs Market based on drug class can be further segmented into Immunomodulators, Immunosuppressants, Interferons and Others. The Immunomodulators Segment held the largest share of the Multiple Sclerosis Drugs market in 2022. This growth is fueled by the surging application of immunomodulators for the treatment of multiple sclerosis and its connected symptoms. Interferon beta and glatiramer acetate (GA) were the earliest immunomodulators certified for the treatment of relapsing-remitting multiple sclerosis (MS) and clinically isolated syndromes. The greater prescription rates are further propelling the growth of the Immunomodulators segment.

Furthermore, the Immunosuppressants segment is estimated to grow at the fastest CAGR of 4.3% during the forecast period 2023-2028 owing to the typical application of immunosuppressants like azathioprine, cyclophosphamide, methotrexate and mitoxantrone for the treatment of Multiple Sclerosis as well as application of immunosuppressants as combination therapy or monotherapy.

Inquiry Before Buying

Multiple Sclerosis Drugs Market Segment Analysis - by Route Of Administration

The Multiple Sclerosis Drugs Market based on the route of administration can be further segmented into Oral, Subcutaneous and Injection. The Injection Segment held the largest share of the multiple Sclerosis Drugs market in 2022. This growth is fueled by the surging count of approvals for multiple sclerosis medications as injections for subcutaneous application in the treatment of ailment. The injection segment is sub-segmented into intramuscular, subcutaneous and intravenous. The increasing application of intravenous (IV) infusions like OCREVUS to treat relapsing or primary progressive forms of Multiple Sclerosis is further propelling the growth of this segment.

Furthermore, the Oral segment is estimated to grow at the fastest CAGR of 5.5% during the forecast period 2023-2028 due to the growing introduction of novel products, assistance in patient satisfaction, boosting therapeutic compliance and the soaring inclination toward oral medications.

Multiple Sclerosis Drugs Market Segment Analysis - by Geography

North America (Multiple Sclerosis Drugs Market) dominated the Multiple Sclerosis Drugs market with a 40% share of the overall market in 2022. The growth is driven by the existence of key players in the North American region. The approval by regulatory authorities is further propelling the growth of the Multiple Sclerosis Drugs Industry, thereby contributing to the Multiple Sclerosis Drugs Industry Outlook, in the North American region. Furthermore, the Asia-Pacific region is estimated to be the region with the fastest CAGR over the forecast period 2023-2028. This growth is fuelled by the factors like enhanced distribution networks of pharmaceutical firms in emerging economies in the Asia-Pacific region. The surging government initiatives are further fueling the progress of the Multiple Sclerosis Drugs Market in the Asia-Pacific region.

Schedule a Call

Multiple Sclerosis Drugs Market Drivers

Surging Approvals for Intramuscular Injections:

As per Healthline, current findings from the National MS Society estimate that almost 1 million people in the U.S. are living with Multiple Sclerosis. In February 2021, the U.S. Food and Drug Administration (FDA) certified an intramuscular injection formulation of Plegridy (peginterferon beta-1a) to treat patients with relapsing forms of multiple sclerosis (MS). This formulation, for injection directly into the muscle, is what is usually utilized to convey the flu shot. As per Biogen, Plegridy’s developer, treatment provided through intramuscular injection is as efficient as the subcutaneous injection formulation. This novel formulation was also currently certified by the European Commission. The surging approvals for intramuscular injections are therefore fueling the growth of the Multiple Sclerosis Drugs Market during the forecast period 2023-2028.

Soaring Treatment Involving Immunomodulators and Immunosuppressants:

As per Healthline, a supposed 2.5 million people live with Multiple Sclerosis globally. Medications certified for application in multiple sclerosis that decrease the frequency of intensifications or gradual infirmity advancement are termed disease-modifying drugs (DMDs). These DMDs can be further categorized as immunomodulators or immunosuppressants. Teriflunomide is an oral immunomodulator that causes anti-inflammatory impacts by restricting dihydroorotate dehydrogenase, a mitochondrial enzyme included in pyrimidine synthesis. It is designated for relapsing forms of MS. The most typically utilized immunosuppressants in Multiple Sclerosis are azathioprine, cyclophosphamide, methotrexate and mitoxantrone. The soaring treatment involving immunomodulators and immunosuppressants is fueling the growth of the Multiple Sclerosis Drugs Industry, thereby contributing to the Multiple Sclerosis Drugs Industry Outlook during the forecast period 2023-2028.

Multiple Sclerosis Drugs Market Challenges

Side Effects of Interferons:

As per MS Discovery Forum, an approximated 200 novel cases are diagnosed every week in the U.S. Interferon beta (IFNbeta) decreases the relapse rate and activity as assessed by serial MRI scanning and ailment advancement of Multiple Sclerosis. Therapy with IFNbeta may be connected with numerous unfavorable reactions. Comparatively repeated side effects involve flu-like symptoms, transient laboratory abnormalities, menstrual ailments and raised spasticity. Dermal injection site reactions happen subsequent to subcutaneous application of IFNbeta-1b and IFNbeta-1a. Likely side effects of IFNbeta involve different autoimmune reactions, capillary leak syndrome, anaphylactic shock, thrombotic-thrombocytopenic purpura, insomnia, headache, alopecia and depression. These issues are thus hampering the growth of the Multiple Sclerosis Drugs Market.

Buy Now

Multiple Sclerosis Drugs Industry Outlook

More focus on pipeline drugs for multiple sclerosis and emerging R&D financing in the pharmaceutical industry are key strategies adopted by players in the Multiple Sclerosis Drugs Market. The top 10 companies in the Multiple Sclerosis Drugs market are:

Bayer AG

Teva Pharmaceutical Industries Ltd.

Novartis AG

Sanofi Inc.

F. Hoffmann-La Roche Ltd.

Celgene Corporation

Acorda Therapeutics, Inc.

Biogen, Inc.

Actelion Pharmaceuticals Ltd. (Johnson & Johnson)

Merck Serono (Merger between EMD Serono and Merck KGaA)

Recent Developments

In October 2021, Novartis declared that it would introduce 41 abstracts at the upcoming 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). The data being introduced covered an all-inclusive MS portfolio. This stressed the firm’s dedication in enhancing the quality of life for people residing with MS at all phases of the ailment.

In June 2021, Novartis marked a collaboration agreement and alternative to acquiring Cellerys. Cellerys is a Zurich-based startup, conducting research on a therapy to combat Multiple Sclerosis (MS). 

In January 2020, Novartis favorably finished the acquisition of The Medicines Company. This included a possibly first-in-class, investigational cholesterol-lowering therapy - inclisiran. The Medicines Company proposed the New Drug Application (NDA) for inclisiran to FDA in December 2019.